5 completed. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
Follow Refractory Malignant Neoplasm: new trials by email Literature Review of Refractory Malignant Neoplasm trials Research Report on Refractory Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Antiretroviral Therapy, Biopsy, Biospecimen Collection - AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Completed | National Cancer Institute (NCI) | 58 | 2016-04-04 | 2024-08-09 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study - Cirrhosis, Hepatitis B Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-01-30 | 2024-11-22 |
| Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Anakinra, Denosumab, Everolimus - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 57 | 2012-06-19 | 2021-02-25 |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 123 | 2012-05-14 | 2026-08-28 |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, BRAF Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 46 | 2012-02-06 | 2021-01-22 |
Neoplasm Metastasis (5) · Neoplasms (5) · Recurrence (4) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (1) · Fibrosis (1) · HIV Infections (1) · Hepatitis B (1) · Hepatitis C (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Sarcoma, Kaposi (1)
Neoplastic Processes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Adenocarcinoma (2) · Blood-Borne Infections (2) · Carcinoma (2) · Communicable Diseases (2) · DNA Virus Infections (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Infections (2) · Liver Diseases (2) · Liver Neoplasms (2) · Neoplasms by Histologic Type (2)
Everolimus (2) · Sorafenib (2) · Antiretroviral Therapy, Highly Active (1) · Biopsy (1) · Crizotinib (1) · Denosumab (1) · Interleukin 1 Receptor Antagonist Protein (1) · Magnetic Resonance Spectroscopy (1) · Receptors, Interleukin-6 (1) · Specimen Handling (1) · Vemurafenib (1) · navitoclax (1) · pembrolizumab (1) · vandetanib (1)
M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (2)
United States (5)
Filip Janku (2) · Brian A Costello (1) · Kathryn Lurain (1) · Sarina Piha-Paul, MD (1)
PMID 25982012, PMID 31154457, PMID 35080914, PMID 39356983, PMID 41680482
P30CA015704 (1), P30CA016672 (1), U01CA154967 (1), UM1CA186686 (1)